Plain-English translation of NCT06459687 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing socazolimab, a new medication, combined with standard chemotherapy drugs (and sometimes an additional medication called bevacizumab) to treat cervical cancer that cannot be cured by surgery or radiation. About half of the 440 participants will receive the new medication with chemotherapy, and the other half will receive a placebo (a dummy medication that looks identical) with the same chemotherapy. Researchers want to see if adding this treatment helps people live longer and improves their quality of life.
Cervical cancer that has spread or come back after treatment remains difficult to cure, and current standard chemotherapy has limitations. This medication works on the immune system to help it fight cancer cells more effectively, so researchers believe combining it with chemotherapy may work better than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of either the new medication or placebo every 3 weeks, combined with standard chemotherapy drugs, for 6 to 8 cycles (about 4–6 months). After that, you will continue receiving either the medication or placebo alone as maintenance therapy every 3 weeks for as long as it continues to help. You will have regular visits for blood tests, scans to measure your tumors, and check-ins about side effects. Some participants may also receive bevacizumab as part of their treatment plan. The trial is double-blind, meaning neither you nor your doctor will know whether you're receiving the actual medication or placebo until the study ends.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China